A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.
about
Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic MiceEffects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes.Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.Safety and Effectiveness of Tofogliflozin in Elderly Japanese Patients with Type 2 Diabetes Mellitus: a Post-Marketing Study (J-STEP/EL Study).Concise and Stereodivergent Synthesis of Carbasugars Reveals Unexpected Structure-Activity Relationship (SAR) of SGLT2 InhibitionUric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin.No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis.Long-term safety and efficacy of tofogliflozin add-on to insulin in patients with type 2 diabetes: results from a 52-week, multicenter, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes.
P2860
Q31117903-3C2667C7-73B9-4F4C-AFB1-F3F7D97B5327Q36057947-39B4B0C9-488F-43E0-BFF3-5131F2F8827FQ36327116-537EE2F4-1734-4BE9-A0D6-FDC107BD70DFQ38908779-8A3E2A50-181E-452D-A415-12B0BAC9CE7EQ38936746-05A88C06-5B5B-4BE3-8E75-342C05935F4EQ40266818-FD0DE475-9CEC-4262-AE4F-2CAE22235361Q40363925-541D9B49-2B37-4926-846E-CBAAEB8B6148Q41039103-6802F012-8BB8-4429-BAE0-81E81789358FQ47419406-24DECFFF-D737-4664-8774-8FD29BDBF9C9Q48189020-405DF015-A1B7-4F72-87C1-F92E10248CEDQ48279607-7ECFE196-DF56-4B92-B328-6803E4D115A7Q55176938-AB725E10-ECFE-48B3-902D-227D69DA4E6D
P2860
A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
A novel and selective sodium-g ...... with type 2 diabetes mellitus.
@en
A novel and selective sodium-g ...... with type 2 diabetes mellitus.
@nl
type
label
A novel and selective sodium-g ...... with type 2 diabetes mellitus.
@en
A novel and selective sodium-g ...... with type 2 diabetes mellitus.
@nl
prefLabel
A novel and selective sodium-g ...... with type 2 diabetes mellitus.
@en
A novel and selective sodium-g ...... with type 2 diabetes mellitus.
@nl
P2093
P2860
P356
P1476
A novel and selective sodium-g ...... with type 2 diabetes mellitus
@en
P2093
A D Christ
C Ciorciaro
T Kadowaki
P2860
P304
P356
10.1111/DOM.12538
P50
P577
2015-08-20T00:00:00Z